. Author manuscript; available in PMC: 2015 May 1.

Published in final edited form as: Clin Gastroenterol Hepatol. 2013 Jul 18;12(5):728–737. doi: 10.1016/j.cgh.2013.06.024

Table 2.

One drug trials +/− RBV

Drug and Trial name	RBV	# Patients / genotype / experience	Treatment Time (wks)	²SVR/Total	SVR (%)	Reference
*Phase II*
¹SOF ELECTRON	+	10 / 2,3 / naive	12	10/10	100%	⁴¹Gane et al 2013
	0	10 / 2,3 / naive	12	6/10	60%
	+	25 / 1 / naive	12	22/25	88%
	+	10 / 1 / null	12	1/10	10%
SOF SPARE	Full: 1.2g or Half: 0.6g daily	60 / 1 / naive [82% AA/ 72% geno 1a]	24	10/10 Full RBV	100%	⁴²Osinusi et al 2013 and CROI 2013 Abstract #157LB
				17/24 Full RBV	68% SVR12
				12/22 half RBV	48% SVR12
*Phase III*
SOF POSITRON	+	207 / 2,3 / naive	12	161/207	78% SVR12	⁴³Jacobson et al. 2013
SOF FISSON	+	256 / 2,3 / naive	12	170/253	67% SVR12	⁴⁴Lawitz et al. 2013
SOF FUSION	+	103 / 2,3 / null	12	50/100	50% SVR12	⁴³Jacobson et al 2013
SOF FUSION	+	98 / 2, 3 / null	16	69/95	73% SVR12	⁴³Jacobson et al 2013

SOF = sofosbuvir

SVR = SVR at 24 wks unless indicated otherwise.